Multi-Year NIH Contract Positions IDRI to Apply Key Immunological Findings Across Diseases

October 24th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle, WA. October 21, 2019 The Infectious Disease Research Institute (IDRI) announced the award of a groundbreaking multi-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). [...]

What Can We Do to End TB?

March 22nd, 2019|Blog|

As we observe World TB Day on March 24, the World Health Organization (WHO) reminds us of the commitment made with the “End TB" strategy: to reduce tuberculosis incidence by 80%, tuberculosis deaths by 90% and to eliminate catastrophic costs that [...]

IDRI Announces Evolution of Leadership Roles; New Focus on Oncology

February 25th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 25, 2019: After 25 years of success in infectious disease research and development, IDRI is poised to continue to make rapid and significant advances in the battle against the world’s deadliest infectious diseases, while expanding [...]

IDRI Partners with Afrigen Biologics and Biovac to Produce Tuberculosis Vaccine

February 21st, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 22, 2019: In an effort to produce vaccines where they are needed most, IDRI (Infectious Disease Research Institute) is collaborating with the Cape Town, South Africa, based biotechnology startup company Afrigen Biologics, founded by the [...]

Sustainable Squalene Replacement Needed for Pharma

February 12th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 12, 2019: IDRI (Infectious Disease Research Institute) is pleased to announce a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover [...]

IDRI Therapeutic Vaccine for TB to Enter Clinical Trial

February 10th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 4, 2019: A clinical trial testing two new therapeutic vaccines, one developed by IDRI (Infectious Disease Research Institute) and another by Archivel Farma, was given the green light to proceed at the inaugural meeting [...]

Observe World Leprosy Day for a Different Reason

January 25th, 2019|Blog|

Despite the successes of multidrug therapy for improved treatment of patients and the advancement of chemoprophylactic regimen to contain infection in earlier stages within asymptomatic infected individuals, transmission of M. leprae – the bacterium that causes leprosy - continues and [...]

Temperature-Stable Experimental Tuberculosis Vaccine Enters Clinical Testing

January 23rd, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Jan. 23, 2019: Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. The trial is being conducted at the Saint Louis University [...]

IDRI Expands Board of Directors with PwC Partner

December 19th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Dec. 19, 2018: Gerry McDougall, a Senior Partner at PricewaterhouseCoopers Health Sciences Practice who serves as the company’s Global Health Science Practice Leader, has joined the Board of Directors of IDRI (Infectious Disease Research Institute). [...]

Can New Drugs Be Tested with Computers? Team Explores Possibility for TB Drugs

December 17th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Dec. 17, 2018: IDRI is partner in a European Union-funded consortium that is focused on demonstrating how advanced computer modelling and simulation can be used to reduce the costs of the clinical trials to test [...]

Load More